The financing round saw participation from existing backers Duquesne Family Office and Bristol Myers Squibb, alongside new investors including Eli Lilly and Company, Catalio Capital Management, and Wasatch Group. These funds are slated to accelerate the ATLAS study, which evaluates the lead candidate [Ac-225]RTX-2358 for advanced sarcomas, and to propel a next-generation radioligand therapy into clinical testing.
In section Releases
Ratio Therapeutics Secures $70 Million to Scale Radiopharmaceutical Pipeline
With a fresh $70 million Series C injection, Boston-based Ratio Therapeutics has pushed its total funding past the $240 million mark. The company intends to channel this capital into its ongoing clinical trials and the aggressive expansion of its proprietary manufacturing infrastructure for targeted cancer treatments.
Beyond current trials, Ratio plans to diversify its oncology pipeline into high-value targets while scaling its manufacturing capacity to meet future demand. CEO Dr. Jack Hoppin stated the capital provides the necessary runway for the company’s fifth IND filing. Sue Meng of Duquesne Family Office noted that the investment underscores the company’s ability to bridge advanced scientific research with the logistical execution required for radiopharmaceutical development.
Comments (0)
No comments yet. Be the first!